title: Role of alpha-adrenergic mechanisms on responses to area postrema stimulation and circulating vasopressin.
abstract: This study evaluated the role of catecholamines in the nucleus tractus solitarius (NTS) on the inhibition of renal sympathetic nerve activity (RSNA) due to direct electrical stimulation of the area postrema. In addition, the effects of catecholaminergic mechanisms in the NTS on the ability of circulating arginine vasopressin (AVP) to modulate arterial baroreflex control of RSNA were evaluated. Electrical stimulation of the area postrema (15 microA, 0.3 ms, 5-80 Hz) produced progressive decreases in RSNA. Responses to area postrema activation were not altered by microinjection of the alpha 1-adrenergic antagonist, prazosin, or vehicle bilaterally into the NTS. Microinjection of the alpha 2-antagonist, yohimbine (4 injections of 20-40 nl, 1 ng/nl), unilaterally into the NTS significantly attenuated the RSNA response to area postrema stimulation. Bilateral injection of yohimbine into the NTS abolished the response to area postrema activation (P < 0.05). Baroreflex inhibition of RSNA was significantly greater during infusion of AVP than during infusion of phenylephrine (slopes = -5.18 +/- 0.39 and -2.64 +/- 0.27 for AVP and phenylephrine, respectively). Microinjection of yohimbine bilaterally into the NTS did not alter the slope of baroreflex control of RSNA for phenylephrine but normalized the slope for AVP (-2.85 +/- 0.54) to that of phenylephrine. Data are consistent with the hypothesis that AVP effects on baroreflex inhibition of RSNA and area postrema-mediated inhibition of RSNA require alpha 2-adrenergic signaling within the NTS.
authors.affiliation: Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia 65211.
authors.forename: E M
authors.initials: EM
authors.lastname: Hasser
authors.forename: V S
authors.initials: VS
authors.lastname: Bishop
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology; D002552:Cerebral Ventricles / Q000502:physiology*; D004558:Electric Stimulation; D007668:Kidney / Q000294:innervation; D008297:Male; D008526:Medulla Oblongata / Q000502:physiology; D008845:Microinjections; D011311:Pressoreceptors / Q000187:drug effects; D011817:Rabbits; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D012018:Reflex / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000502:physiology; D014667:Vasopressins / Q000097:blood*; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D011942:Receptors, Adrenergic, alpha; D014667:Vasopressins; D001127:Arginine Vasopressin; D015016:Yohimbine